triiodothyronine has been researched along with bim 23a760 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barbieri, F; Culler, MD; Ferone, D; Florio, T; Gatti, M; Gatto, F; Giusti, M; Hofland, LJ; Minuto, F; Ravetti, JL; Saveanu, A; Schulz, S; Wurth, R; Zona, G | 1 |
1 other study(ies) available for triiodothyronine and bim 23a760
Article | Year |
---|---|
Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.
Topics: Adenoma; Adult; Cabergoline; Cell Proliferation; Dopamine; Dopamine Agonists; Drug Synergism; Ergolines; Gene Expression; Humans; Immunohistochemistry; Male; Octreotide; Pituitary Neoplasms; Protein Isoforms; Receptors, Dopamine D2; Receptors, Somatostatin; Reverse Transcriptase Polymerase Chain Reaction; Somatostatin; Thyrotropin; Thyroxine; Treatment Outcome; Triiodothyronine; Tumor Cells, Cultured | 2012 |